Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (192)	3/31/1998 11:26:00 AM
From: Biomaven	Respond to of 399

<<This is repetitive and boring. It sounds just like a dozen other ARQL releases. That's what happens when a fine business plan is well executed.>> I like it <G>. The art of biotech investing is to find the right combination of stocks (like INCY and ARQL) where you are happily bored and those (like MOGN) where you are happily excited. Peter

To: Dr. John M. de Castro who wrote (192)	3/31/1998 12:48:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 399

John: This deal is actually ("Immunex will elect") structured a bit differently. It had to be, given AHP. However, that's a plus.... this is a biotech-biotech deal that has tangential big bucks behind it. Moreover, this is a deal that allows for multiple products from a single program of a multiple-program company (IMNX). This is a great match. Agree completely with your sentiment. Now, Gordon, let's see that IND that's supposed to break up the boredom. Cheers! Rick